PDS Biotechnology (PDSB) Long-Term Debt Issuances (2015 - 2025)
PDS Biotechnology's (PDSB) quarterly Long-Term Debt Issuances came in at -$1.1 million in Q4 2025, down 207.31% on a QoQ basis from $1.0 million in Q3 2025.
PDS Biotechnology (PDSB) Long-Term Debt Issuances (2015 - 2025) Analysis & Trends
PDS Biotechnology (PDSB) has 3 years of Long-Term Debt Issuances data on file, last reported at -$1.1 million in Q4 2025.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$73089.0 (changed N/A YoY) and the FY2025 annual result came in at $18.2 million, changed N/A from the prior year.
- Long-Term Debt Issuances fell to -$1.1 million in Q4 2025, from $1.0 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $1.0 million in Q3 2025 to a low of -$1.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.07 Mn |
| Dec 31, 2025 | -1.07 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Sep 30, 2016 | 11.02 Mn |
| Sep 30, 2016 | 11.02 Mn |
| Mar 31, 2015 | 3.00 Mn |
| Mar 31, 2015 | 3.00 Mn |